SCHEMBL20494180

SCHEMBL20494180

COc1ccc(Oc2nc(C(=O)NC(C)c3ccc(C(F)(F)F)cc3)cc(=O)[nH]2)cc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18247967 1.00 PDE2A (1.00) PDE2A
SCHEMBL18249143 0.86 PDE2A (0.79) PDE2A
SCHEMBL20494056 0.86 PDE2A (0.79) PDE2A
SCHEMBL18249362 0.86 PDE2A (0.75) PDE2A
SCHEMBL20494211 0.86 PDE2A (0.75) PDE2A
SCHEMBL16867689 0.82 PDE2A (1.00) PDE2A
SCHEMBL19571234 0.82 PDE2A (1.00) PDE2A
SCHEMBL18255575 0.81 PDE2A (1.00) PDE2A
SCHEMBL18247966 0.81 PDE2A (0.68) PDE2A
SCHEMBL18247984 0.80 PDE2A (0.91) PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10285989-B2 Pyrimidinone amide compounds as PDE2 inhibitors MERCK SHARP & DOHME CORP. (US) 2019-05-14 US claimed
US-20180256575-A1 PYRIMIDINONE AMIDE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-09-13 US claimed
US-10285989-B2 Pyrimidinone amide compounds as PDE2 inhibitors MERCK SHARP & DOHME CORP. (US) 2019-05-14 US disclosed
US-20180256575-A1 PYRIMIDINONE AMIDE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10285989-B2 Pyrimidinone amide compounds as PDE2 inhibitors PDE12, PDE2A, PDE4D PDE2A 2/4885
US-20180256575-A1 PYRIMIDINONE AMIDE COMPOUNDS AS PDE2 INHIBITORS PDE12, PDE2A, PDE4D PDE2A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.